Gefitinib, a pharmacological inhibitor of EGFR inhibits growth and invasion of urothelial cell lines in which erbB1 is constitutively activated

被引：0
|
作者：
Nicole, G
Vordos, D
Daher, A
Maillé, P
Bakkar, A
Pages, C
Jouault, H
Abbou, CC
de Medina, SGD
Chopin, DK
机构：
来源：
JOURNAL OF UROLOGY | 2005年 / 173卷 / 04期
关键词：
D O I：
10.1016/S0022-5347(18)34818-3
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
578
引用
收藏
页码：158 / 158
页数：1
相关论文
共 46 条
  • [31] Peroxisome proliferator-activated receptor- activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1
    Pang, Xiaojuan
    Wei, Yinna
    Zhang, Ya
    Zhang, Minyue
    Lu, Yan
    Shen, Pingping
    CANCER SCIENCE, 2013, 104 (06) : 672 - 680
  • [32] Ectopic expression of the ErbB-3 binding protein Ebp1 inhibits growth and induces differentiation of human breast cancer cell lines
    Lessor, TJ
    Yoo, JY
    Xia, XM
    Woodford, N
    Hamburger, AW
    JOURNAL OF CELLULAR PHYSIOLOGY, 2000, 183 (03) : 321 - 329
  • [33] The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423
    Hashimoto, Hisashi
    Sudo, Tamotsu
    Maruta, Hiroshi
    Nishimura, Ryuichiro
    DRUG DISCOVERIES AND THERAPEUTICS, 2010, 4 (01): : 1 - 4
  • [34] Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
    Okabe, Takafumi
    Okamoto, Isamu
    Tsukioka, Sayaka
    Uchida, Junji
    Iwasa, Tsutomu
    Yoshida, Takeshi
    Hatashita, Erina
    Yamada, Yuki
    Satoh, Taroh
    Tamura, Kenji
    Fukuoka, Masahiro
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (03) : 599 - 606
  • [35] Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis - Evidence for heterogeneity of tumor cell lines
    Alexia, C
    Lasfer, M
    Groyer, A
    SIGNAL TRANSDUCTION PATHWAYS, CHROMATIN STRUCTURE, AND GENE EXPRESSION MECHANISMS AS THERAPEUTIC TARGETS, 2004, 1030 : 219 - 229
  • [36] Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines
    Kalish, LH
    Kwong, RA
    Cole, IE
    Gallagher, RM
    Sutherland, RL
    Musgrove, EA
    CLINICAL CANCER RESEARCH, 2004, 10 (22) : 7764 - 7774
  • [37] Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers
    Wang, Xiaolong
    Li, Bingsheng
    Ciotkowska, Anna
    Rutz, Beata
    Erlander, Mark G.
    Ridinger, Maya
    Wang, Ruixiao
    Tamalunas, Alexander
    Waidelich, Raphaela
    Stief, Christian G.
    Hennenberg, Martin
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 873
  • [38] Growth response of human colorectal tumour cell lines to treatment with BIBW2992, an irreversible EGFR/HER1 and HER-2 tyrosine kinase inhibitor
    Khelwatty, S.
    Essapen, S.
    Seddon, A. M.
    Modjtahedi, H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 51 - 51
  • [39] A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-β1 signaling cascade
    Kobayashi, H
    Suzuki, M
    Tanaka, Y
    Kanayama, N
    Terao, T
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (10) : 7790 - 7799
  • [40] Insect cell production of a secreted form of human α1-proteinase inhibitor as a bifunctional protein which inhibits neutrophil elastase and has growth factor-like activities
    Curtis, H
    Sandoval, C
    Oblin, C
    Difalco, MR
    Congote, LF
    JOURNAL OF BIOTECHNOLOGY, 2002, 93 (01) : 35 - 44
12345